Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer therapy it co-develops with Pfizer (NYSE:PFE).

Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback for a drug the company once called a blockbuster in the making.

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically significant results in others in a late-stage study.